2019
921P Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
McGregor B, O’Donnell P, Balar A, Petrylak D, Rosenberg J, Yu E, Quinn D, Shah S, Pinelli J, Hepp Z, Galsky M. 921P Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1. Annals Of Oncology 2019, 30: v367-v368. DOI: 10.1093/annonc/mdz249.020.Peer-Reviewed Original ResearchBristol-Myers SquibbGenentech/RochePlatinum-containing chemotherapyEnfortumab vedotinVisual analog scaleCheckpoint inhibitorsCohort 1EMD SeronoSeattle GeneticsAstellas Pharma Inc.Metastatic urothelial cancer patientsPatient-reported outcome measuresSelf-rated health statusPain/discomfortUrothelial cancer patientsGreater symptom burdenAnxiety/depressionEQ-5D utilitiesMUC patientsPrior chemotherapyExploratory endpointsSymptom burdenVAS scoresCancer QualityCycle 5
2013
Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial.
Small E, Higano C, Kantoff P, Whitmore J, Frohlich M, Petrylak D. Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. Journal Of Clinical Oncology 2013, 31: 74-74. DOI: 10.1200/jco.2013.31.6_suppl.74.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerSymptomatic metastatic castration-resistant prostate cancerCase report formsProtocol amendmentMedical reviewIMPACT trialCastration-resistant prostate cancerPrespecified secondary end pointsEnd pointECOG performance status 1Autologous cellular immunotherapyAverage pain scoreOpioid analgesic usePlacebo-treated patientsSecondary end pointsIndependent baseline predictorsPerformance status 1Objective disease progressionVisual analog scaleCox regression modelKaplan-Meier estimatesAsymptomatic ptsPrimary radiotherapyAnalgesic useCancer pain